Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


16.04.2018

2 Gastroenterology
2 Hepatology
1 J Gastroenterol
2 J Hepatol
3 Lancet Gastroenterol Hepatol
2 PLoS One
1 Virology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Gastroenterology

  1. MANDORFER M, Reiberger T, Peck-Radosavljevic M
    Monitoring the Evolution of Portal Hypertension After Sustained Virologic Response.
    Gastroenterology. 2018 Mar 8. pii: S0016-5085(18)30150.
    PubMed     Text format    

  2. TAVIS JE, Lomonosova E
    NVR 3-778 Plus Pegylated Interferon-alpha Treatment for Chronic Hepatitis B Viral Infections: Could 1 + 1 = 3?
    Gastroenterology. 2018;154:481-482.
    PubMed     Text format    


    Hepatology

  3. HOUSSEL-DEBRY P, Coilly A, Fougerou-Leurent C, Jezequel C, et al
    12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation.
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29918.
    PubMed     Text format     Abstract available

  4. WENDUM D, Layese R, Ganne-Carrie N, Bourcier V, et al
    Influence of progenitor-derived regeneration markers on HCV-related cirrhosis outcome (ANRS CO12 CirVir cohort).
    Hepatology. 2018 Apr 10. doi: 10.1002/hep.29927.
    PubMed     Text format     Abstract available


    J Gastroenterol

  5. TSUJI K, Kurosaki M, Itakura J, Mori N, et al
    Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Gastroenterol. 2018 Apr 6. pii: 10.1007/s00535-018-1455.
    PubMed     Text format     Abstract available


    J Hepatol

  6. ABDEL-MONEIM A, Aboud A, Abdel-Gabbar M, Zanaty MI, et al
    A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30174.
    PubMed     Text format    


  7. EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Apr 9. pii: S0168-8278(18)31968.
    PubMed     Text format    


    Lancet Gastroenterol Hepatol

  8. GUPTA N, Nsanzimana S
    Is hepatitis C elimination possible in sub-Saharan Africa? The case of Rwanda.
    Lancet Gastroenterol Hepatol. 2018;3:302-303.
    PubMed     Text format    

  9. THE LANCET GASTROENTEROLOGY HE
    Treatment of hepatitis C: momentum still needed.
    Lancet Gastroenterol Hepatol. 2018;3:289.
    PubMed     Text format    

  10. DORE GJ
    Striving for hepatitis C virus elimination or control?
    Lancet Gastroenterol Hepatol. 2018;3:295-297.
    PubMed     Text format    


    PLoS One

  11. FACENTE SN, Grebe E, Burk K, Morris MD, et al
    Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination.
    PLoS One. 2018;13:e0195575.
    PubMed     Text format     Abstract available

  12. LU Y, Jin X, Duan CA, Chang F, et al
    Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naive patients in China.
    PLoS One. 2018;13:e0195117.
    PubMed     Text format     Abstract available


    Virology

  13. KRAPCHEV VB, Rychlowska M, Chmielewska A, Zimmer K, et al
    Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.
    Virology. 2018;519:33-41.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: